Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial

Research output: Contribution to conferencePosterpeer-review

Abstract

Fenretinide is a pro-apoptotic, cytotoxic, synthetic Vitamin A analogue with application in the treatment of Ewing’s sarcoma. For pediatric study, a ‘cookie dough’ formulation had been developed, improving upon an existing corn oil formulation. We report on a simplified capsular formulation of Fenretinide with the novel solubility and bioavailability enhancing lipid matrix, Lym-X-Sorb™.
Original languageEnglish
Pages1433-1434
Publication statusPublished - 3 Sep 2010
EventUK-PharmSci 2010 – The Science of Medicines - Nottingham, United Kingdom
Duration: 1 Sep 20103 Sep 2010

Conference

ConferenceUK-PharmSci 2010 – The Science of Medicines
Country/TerritoryUnited Kingdom
CityNottingham
Period1/09/103/09/10

Fingerprint

Dive into the research topics of 'Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial'. Together they form a unique fingerprint.

Cite this